



Continuation of Substance of Interview including description of the general nature of what was discussed:

An agreement was initially reached on 10/22/2010 to limit the claims to cyprodinil as component (B). The Examiner mentioned however that a search update needs to be done and that he was aware of many similar published applications by applicant, which require review for double patenting issues. On 10/25/2010, the Examiner called to inform Mr. Grandinetti and Mr. Lewis that U.S. Patent 7,776,892 raised obviousness type double patenting issues. The Examiner stated that he would write up an Office action wherein claims are rejected. .